Skip to main content

Unable to load price data. Sorry.



CAPS Rating: No stars

A biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

27 Outperform
11 Underperform

All-Star Players

5 Outperform
3 Underperform

Wall Street

0 Outperform
0 Underperform


The best Bull and Bear pitches based on recency and number of recommendations.

vevyvevyvicket (69.05)
Submitted January 27, 2007

They are in a 'lower risk' biotech category - the kind I like. And should get FDA approval for Zingo. I am not sure about 4975 - their phase 3 pain drug. Some studies seem promising whereas results from other clinical trials have weak statistics that… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

Recent Community Commentary

Read the most recent pitches from players about ANSVQ.


Member Avatar biovestor (39.78) Submitted: 6/30/2008 9:56:50 AM : Outperform Start Price: $3.00 NASDAQ OTC:ANSVQ Score: -367.78

A specialty, small/micro-cap pharma & drug delivery company with approved niche product Zingo for kids and pending sNDA to expand label for adult use as local anesthetic befor needlestick procedures. Adlea is a potential blockbuster in Phase 2/3 trials as a long-acting injection for pain relief lasting weeks to months.


Member Avatar robertvince (< 20) Submitted: 6/3/2008 8:07:12 AM : Outperform Start Price: $3.55 NASDAQ OTC:ANSVQ Score: -338.58

Zingo should get the cash flowing and allow their pipeline some time to mature. Zingo is a topical anti-pain cream given prior to an injection to children to lessen the sting of the needle. Think about that for a second.... its the most terrifying part of any doctor visit, if a parent can tell the kid they have a 'new cream' that makes a needle pain free, they're gonna give it to the kids, even if they weren't scared of needles to begin with. Zingo is FDA approved, and the stock is down. They're not selling it till June 08 at the earliest, so the numbers haven't started to roll in yet, when they do, it will be too late to buy the stock. Get in while the getting is good!


Member Avatar poppinkid (< 20) Submitted: 5/8/2008 9:18:15 PM : Outperform Start Price: $3.48 NASDAQ OTC:ANSVQ Score: -340.79

Zingo is underrated. Adlea is a big seller. I am a fan at these prices. If Adlea is FDA approved and ZIngo becomes the 200M product it can be, this is a 5 bagger in 2 years.


Find the members with the highest scoring picks in ANSVQ.

Score Leader


Fatiggy (< 20) Score: +372.18

The Score Leader is the player with the highest score across all their picks in ANSVQ.

Member Name Member
Call Time
Score Commentary
Fatiggy < 20 8/4/2008 Underperform 5Y $2.68 -99.88% +272.30% +372.18 0 Comment
CCMFX < 20 6/27/2008 Underperform NS $2.93 -99.89% +268.07% +367.96 0 Comment
ChristensenFund 24.77 7/1/2008 Underperform NS $2.87 -99.89% +267.01% +366.90 0 Comment
DustinMiller < 20 9/18/2006 Underperform 1Y $6.75 -99.95% +266.44% +366.39 0 Comment
PoorForLife 94.92 11/20/2006 Underperform 5Y $6.61 -99.95% +244.73% +344.68 0 Comment
dragondragon18 98.11 1/15/2008 Underperform 1Y $5.62 -99.94% +241.87% +341.82 0 Comment
coldcabbage < 20 2/8/2007 Underperform 1Y $8.06 -99.96% +233.52% +333.48 0 Comment
tharlow 80.85 8/20/2007 Underperform 1Y $5.80 -99.94% +229.89% +329.84 2 Comments
honcharella 57.08 8/17/2007 Underperform 1Y $6.98 -99.95% +229.13% +329.09 0 Comment
qbit14 54.07 10/26/2007 Underperform NS $5.99 -99.95% +211.39% +311.34 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ANSVQ.